In Vitro Assessments of Antimicrobial Activity

Closed Pre-Solicitation Posted

Not the latest version. See the latest solicitation from .

Solicitation number
75N93024R00024
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Bethesda, Maryland, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to support in vitro testing and assessment of therapeutic compounds against infectious agents. The procurement aims to evaluate potential medical countermeasures across four distinct task areas: Bacteria/Fungi/Toxins, Viruses, Parasites/Vectors, and New Techniques for Culturing Difficult Pathogens. Qualified organizations can submit proposals for one or multiple task areas, but must provide separate proposals for each. The Request for Proposal (RFP) will be electronically available on SAM.gov around December 30, 2024, with proposals required to be submitted through NIAID's electronic Contract Proposal Submission (eCPS) website. Offerors must demonstrate capabilities to perform comprehensive in vitro assessments and may utilize subcontractors, partnerships, or consultants, but will retain full responsibility for all project deliverables and management.

Currently, fourteen institutions hold base contracts from the 2019 In Vitro Assessments of Antimicrobial Activity program, which have previously supported rapid responses to emerging threats like SARS-CoV-2. The solicitation supports research across more than 270 infectious agents and vectors, with potential outcomes including advancement of medical countermeasures toward approval, licensure, and potential inclusion in the Strategic National Stockpile. While specific award values are not detailed, NIAID anticipates awarding multiple contracts to organizations demonstrating technical capabilities across the specified task areas. The program is categorized under NAICS code 541714 for Research and Development in Biotechnology and PSC code AN11 for Health R&D Services. Proposals will be evaluated based on technical capabilities, expertise, and ability to meet the comprehensive in vitro testing requirements across different infectious disease domains.

Notice text

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement to support in vitro testing assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases.

Description

NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts.  The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing.  The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide capability in a broad range of in vitro testing capabilities to assess promising candidate countermeasures against the more than 270 infectious agents and vectors that are within the purview of DMID.

In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data to be used by NIAID partners at other agencies within the Department of Health and Human Services.  Such data will facilitate the advancement of promising candidate medical countermeasures against priority emerging and bioterror infectious agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile.  

In 2019, fourteen (14) institutions were awarded base contracts under the In Vitro Assessments of Antimicrobial Activity IDIQ contract program. Its overarching goal was to provide broad capability in in vitro methods to evaluate activity of candidate countermeasures against the full range of infectious agents in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging threats such as SARS-CoV-2 and other emergency preparedness priorities.

NIAID anticipates awarding multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas described below. Offerors may submit to multiple Task Areas where they are capable to best meet the overall Task Area requirements, however, they must submit separate proposals for each of these Task Areas.  Offerors will be considered for contracts only in the Task Area(s) included in their proposal(s), and successful Contractors may compete for task orders only in the Task Area(s) in which they are selected for award.   Sample Task Orders will be provided in the Request for Proposal (RFP) solely to evaluate Offeror responses and capabilities. The Task Areas of this solicitation are as follows:

Task Area A – Bacteria, Fungi, and Toxins

Task Area B – Viruses

Task Area C – Parasites and Vectors

Task Area D – New Techniques to Culture Difficult-to-Grow Pathogens

The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise, or facilities required to perform all activities set forth in the Statement of Work.  Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through subcontracts, partnership or consortia agreements, and/or use of consultants. However, Contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. 

Any responsible offeror may submit a proposal that will be considered by the Agency. This RFP will be available electronically on/about December 30, 2024, and may be accessed through SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable.

For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit."

Files

File Type Posted
75N93024R00024 - Pre-Solicitation Notice.pdf PDF

Notice history

Notice Type Posted
In Vitro Assessments of Antimicrobial Activity Latest solicitation Solicitation
This notice Pre-Solicitation
In Vitro Assessments of Antimicrobial Activity Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Pre-Clinical Models of Infectious Diseases United States · NAICS 541714 National Institute of Allergy and Infectious Diseases No set-aside
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases NAICS 541715 National Institute of Allergy and Infectious Diseases No set-aside
NAHLN Diagnostic Testing Services Ames, Iowa 50010, United States · NAICS 541940 Marketing and Regulatory Programs Business Services No set-aside
Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response Washington, District of Columbia 20024, United States · NAICS 541714 Office of the Assistant Secretary for Preparedness and Response No set-aside
6550--Cepheid GeneXpert Testing Supplies Beckley Vamc Clarksburg Vamc Vamhcs Washington Vamc · NAICS 325413 Veterans Integrated Service Network 5 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors